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Adult T cell Leukaemia Lymphoma [ATL], a mature T-cell
neoplasm has been classified into 4 subtypes: smouldering;
chronic leukaemia; lymphoma and acute leukaemia. The
diagnosis depends on clinical features, the immunopheno-
type, and demonstration of HTLV-1 infection & ideally of
monoclonal proviral integration. The typical immunophe-
notype of ATL is not specific. The methods used to detect
monoclonality are labour-intensive and/or expensive and
are not widely available. We developed a flow cytometry
assay for diagnosis and monitoring of ATL. We performed
11-colour immunophenotyping, HTLV-1 proviral quantifi-
cation and proviral integration site [IS] analysis on 53 sam-
ples from 36 patients [25 non ATL HTLV-1-infected,
11 chronic/smouldering ATL], 3 uninfected individuals
and 2 HTLV-1-immortalized cell lines. The non-ATL
patients had CD127+ & CCR7-lo expression in CD4+
CD25+CCR4+ cells, and a polyclonal distribution on IS
analysis. FourATL patients had CD127+ & CCR7-lo
expression in CD4+CD25+CCR4+ cells and polyclonal
distribution on IS analysis. These patients had an excellent
outcome achieving remission with either PUVA or no
therapy. Eight ATL patients had CD127-lo expression on
CD4+ CD25+ CCR4+ cells with mono/oligoclonal distri-
bution on IS analysis. One of nine patients with chronic
ATLL had high CCR7 expression. Foxp3 expression was
variable. All 8 patients required systemic ATL treatment
and longitudinal study of 5 patients found the change in
frequency of CD4+CD25+CCR4+ to correlate with PVL
whilst CD127 expression correlated with IS analysis
(p<0.005) and disease remission status. CD127 expression
appears to be useful to identify patients needing treatment
and for monitoring the treatment of chronic ATL.
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